We demonstrated that amlexanox substantially improved glucose tolerance, fatty liver, and insulin sensitivity; reduced hepatic steatosis in genetically obese and diet-induced obese mice (30, 33, 34); and significantly reduced hemoglobin A1c (HbA1c) levels in a subset of patients with diabetes with high basal levels of systemic inflammation (35). The gene discussed is INS; the disease is fatty liver disease.